b"Scientific Session Abstracts SATURDAY APRIL 20, 2024 Table 2: Procedural and short-term outcomes among TF-TAVR and AA patientsAll patients TransfemoralAlternativep-ValueTAVR TAVR(N=3441) (N=3278) (N=l63)Any complication 513 (14.9) 495 (15.1) 18 (11.0) .177CVAor TIA 59 (1.7) 52 (1.6) 7 (4.3) .020Cerebral protection device248 (7.2) 243(7.4) 5 (3.0) .001usePermanent pacemaker52 (1.5) 51 (1.6) 1 (0.6) .516implantationCoronary obstruction 15 (0.4) 13 (0.4) 2 (1.2) .158Valve embolization 4 (0.1) 4 (0.1) 0 (0) .822Aortic dissection 15 (0.4) 15 (0.5) 0 (0) .480Major vascular complication 81 (2.4) 79 (2.4) 2 (1.2) .436Minor vascular complications 87 (2.5) 83 (2.5) 4 (2.4) .599Life threatening bleeding 15 (0.4) 14 (0.4) 1 (0.6) .520Major bleeding 78 (2.3) 77 (2.3) 1 (0.6) .182Minor bleeding 104 (3.0) 97 (3.0) 7 (4.3) .344Acute renal failure 263 (7.6) 244 (7.4) 19 (11.6) .068New onset Dialysis 4 (0.1) 4 (0.1) 0 (0) .82230-day death (total) 31 (0.9) 25 (0.8) 6 (3.7) .01330-day death (2017-2021) 13 (0.4) 12 (0.4) 1(0.6) .412CVA, cerebrovascular accident; TIA,transient ischemic attack.Data are presented as the number of patients (column%). P-value is calculated with the Kruskal-Wallis test for continuous variables and chi-square or Fisher's exact test for categorical variables as appropriate.Continuous variable presented as median and IQR while categorial variable as numbers and %.58SOUTHERN CALIFORNIA VASCULAR SURGICAL SOCIETY"